← Eichor
Condition: Cd19 Bcma Car T Cells Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Cd19 Bcma Car T Cells

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma
EARLY_Phase 1 · 1 location(s) · Shanghai Cell Therapy Group Co.,Ltd · NCT06732232An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treatin
EARLY_Phase 1 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT07101705An Exploratory Clinical Study on the Safety and Efficacy of Anti-CD19/BCMA U CAR-T Cells in the Treatment of Relapsed/Re
EARLY_Phase 1 · 1 location(s) · Changhai Hospital · NCT07241468UCAR T-cell Therapy Targeting CD19/BCMA in Relapsed/Refractory Autoimmune Hemolytic Anemia
EARLY_Phase 1 · 1 location(s) · The Second Hospital of Anhui Medical University · NCT07530380Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Rel
EARLY_Phase 1 · 1 location(s) · Changhai Hospital · NCT07246096Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma
NA · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT07359014Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT06428188CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
Phase 1 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07315087BCMA-CD19 cCAR-T for the Treatment of Refractory Inflammatory Myopathy
Phase 1 · 1 location(s) · iCell Gene Therapeutics · NCT07715136BCMA-CD19 CCAR T Cell Treatment of Refractory Immune Thrombocytopenia Associated with Autoimmune Diseases
Phase 1 · 1 location(s) · iCell Gene Therapeutics · NCT06787989CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies
EARLY_Phase 1 · 1 location(s) · Zhejiang University · NCT04603872A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.
EARLY_Phase 1 · 1 location(s) · Nanjing Bioheng Biotech Co., Ltd. · NCT07203404CD19/BCMA CAR-T Cell Therapy for Refractory/Moderate-to-severe Systemic Lupus Erythematosus
Phase 1 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06349343CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease
Phase 1 · 1 location(s) · The Children's Hospital of Zhejiang University School of Med · NCT07305116A Clinical Study of Dual-Target, Universal CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus
Phase 1 · 3 location(s) · Hangzhou Qihan Biotech Co., Ltd. · NCT07444307CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases
Phase 1 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06941129A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multipl
EARLY_Phase 1 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT07429721A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regi
Phase 3 · 138 location(s) · AstraZeneca · NCT07391657Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease
EARLY_Phase 1 · 1 location(s) · Tongji Hospital · NCT06497361Allogeneic UCB-derived, Dual-targeting BCMA/CD19 CAR-T for Relapsed/Refractory Multiple Myeloma
Phase 1 · 1 location(s) · Xi'an No.3 Hospital · NCT07139509Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosi
Phase 1 · 9 location(s) · Gracell Biotechnologies (Shanghai) Co., Ltd. · NCT07250269A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma
Phase 1/Phase 2 · 10 location(s) · Gracell Biotechnologies (Shanghai) Co., Ltd. · NCT06235229Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune D
NA · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT07558850Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in
EARLY_Phase 1 · 1 location(s) · Tianjin Huanhu Hospital · NCT06939166Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07523555A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors
EARLY_Phase 1 · 1 location(s) · YANRU WANG · NCT06976437A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
Phase 1/Phase 2 · 18 location(s) · AstraZeneca · NCT06897930Universal CAR-T Cells Targeting Multiple Myeloma
Phase 1 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT06006741Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease
EARLY_Phase 1 · 1 location(s) · The Children's Hospital of Zhejiang University School of Med · NCT07507201AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Phase 1/Phase 2 · 36 location(s) · AstraZeneca · NCT05850234
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.